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OBJECTIVE: Vitamin D deficiency has been related to diabetes, hypertension, hyperlipidemia and peripheral
vascular disease. In this study, we aimed to investigate the role of vitamin D status in non-alcoholic fatty liver
disease.
METHODS: We included 211 consecutive subjects to examine the presence of non-alcoholic fatty liver disease.
Of these subjects, 57 did not have non-alcoholic fatty liver disease and 154 had non-alcoholic fatty liver disease.
RESULTS: The non-alcoholic fatty liver disease group had significantly higher fasting blood glucose (p=0.005),
uric acid (p=0.001), aspartate aminotransferase (p,0.001), alanine aminotransferase (p,0.001), c-glutamyl-
transferase (p,0.0001), alkaline phosphatase (p = 0.028), HbA1c (p,0.001), ferritin (p,0.001), insulin
(p=0.016), C-peptide (p=0.001), HOMA-IR (p=0.003), total cholesterol (p=0.001), triglyceride (p=0.001) and
white blood cell (p=0.04) levels. In contrast, the non-alcoholic fatty liver disease group had significantly lower
25(OH)D levels (12.3¡8.9 ng/dl, p,0.001) compared with those of the control group (20¡13.6 ng/dl).
CONCLUSIONS: In this study, we found lower serum 25(OH)D levels in patients with non-alcoholic fatty liver
disease than in subjects without non-alcoholic fatty liver disease. To establish causality between vitamin D and
non-alcoholic fatty liver disease, further interventional studies with a long-term follow-up are needed.
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& INTRODUCTION
Although the main function of vitamin D is to regulate
bone metabolism, its deficiency has been related to many
other organ systems. Vitamin D deficiency was previously
shown to be associated with an increase in the prevalence
of diabetes, hypertension, hyperlipidemia and peripheral
vascular disease (1). Vitamin D levels were also highly
associated with coronary artery disease, myocardial infarc-
tion, heart failure, stroke and incident death (1). Vitamin D
levels have been additionally associated with obesity,
inflammation and insulin resistance (2). Furthermore, it
was shown that vitamin D administration decreases free
fatty acid (FFA)-induced insulin resistance in experimental
models (3).
Previous studies have shown that non-alcoholic fatty liver
disease (NAFLD) is frequently associated with abdominal
obesity, dyslipidemia, insulin resistance and type 2 diabetes
and may indeed be another component of metabolic
syndrome (4). NAFLD has also been associated with an
increased risk of cardiovascular disease among type 2
diabetic patients, independent of glycemic control and the
presence of metabolic syndrome (5).
The very few studies that have examined the possible
effect of vitamin D on NAFLD (6,7), which is also related to
diabetes mellitus, obesity, dyslipidemia and insulin resis-
tance, have yielded contradictory results. No interventional
studies have investigated the possible effect of vitamin D
supplementation on the progression of NAFLD. In the
present study, we aimed to investigate the association
of vitamin D status, insulin resistance and the urinary
albumin/creatinine ratio with NAFLD in winter.
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& MATERIALS AND METHODS
The work was performed in accordance with the
Declaration of Helsinki.
Population
In this study, we included 232 consecutive subjects who
were referred to our endocrinology and gastroenterology
outpatient clinics between November 2010 and March 2011.
The patients who were diagnosed with NAFLD comprised
the patient group and the subjects without NAFLD
comprised the control group. The inclusion criteria were
no history of excessive alcohol consumption, defined as an
average consumption of alcohol of .30 g/day in men and
,20 g/day in women; negativity for hepatitis B surface
antigen and antibodies to hepatitis C virus (HCV); and an
absence of cirrhosis. Other chronic liver diseases, such as
autoimmune hepatitis, Wilson’s disease and hemochroma-
tosis were excluded by analyzing autoimmune markers of
hepatitis, serum ceruloplasmin and ferritin levels, respec-
tively. Antinuclear antibody (ANA), anti-smooth muscle
antibody (ASMA), anti-mitochondrial antibody (AMA) and
anti-liver-kidney microsomal-1 antibody (anti-LKM-1) were
used to distinguish autoimmune liver diseases. In total, 16
patients with HBsAg (+), 3 patients with anti-HCV antibody
(+) and 2 patients with autoimmune hepatitis antibodies
were excluded from the study. After these patients were
excluded, 211 patients were included in the study.
Patients taking vitamin supplements and wearing head-
scarves were excluded. Anthropometric measurements
were recorded for each subject. The study protocol was in
accordance with the Declaration of Helsinki and was
approved by the local ethics committee. Each patient gave
written informed consent before enrollment and the study
was conducted according to the rules of good clinical
practice.
Serum samples
Fasting blood samples were obtained after a 12-hour fast
by venipuncture of the large antecubital veins without
stasis. The samples were then centrifuged immediately, and
the plasma was separated and stored at -80 C˚. To avoid
variation, all samples were studied on the same day using
the same kit.
Biochemical analysis
Fasting serum insulin and C-peptide levels were mea-
sured by a Liaison Immunoluminometric Assay (DiaSorin
Inc., Stillwater, MN, USA). HbA1c analyses were performed
using an automated Tosoh G7 HbA1c Analyzer (Tosoh
Corporation, Tokyo, Japan). Urine microalbumin levels
were measured by a Beckman Coulter Immage nephelo-
metric tool (Immage Immunohistochemistry System, CA,
USA). The levels of 25(OH)D were measured using a 25OH-
VIT.D3-RIA-CT kit (Catalog No.: KIP1961) (Biosource,
Neville, Belgium) from RIA (normal range: 30-100 ng/ml).
NAFLD evaluation
Liver ultrasonography (US) was performed to assess the
degree of steatosis. All US was performed by the same
operator, who was unaware of the aims of the study and
was blinded to the laboratory values using a General
Electric Logic 5 apparatus equipped with a convex 3.5 MHz
probe. Liver steatosis was scored semiquantitatively on a
scale of 0-3: 0: absent; 1: mild; 2: moderate; and 3: severe.
Steatosis was graded based on the description by
Saverymuttu et al., in which abnormal intensity, high-level
echoes arising from the hepatic parenchyma, a liver-kidney
difference in echo amplitude, echo penetration into the deep
portion of the liver and clarity of the liver blood vessel
structures were assessed (8).
Statistics
Statistical Package for the Social Sciences (SPSS) version
15.0 was used for the analysis. The distribution of the data
was assessed using a one-sample Kolmogorov-Smirnov test.
Normally distributed continuous variables were expressed
as the mean ¡ SD, skew-distributed continuous variables
were expressed as the median (minimum-maximum) and
categorical variables were expressed as the number and
percentage. For comparison of categorical variables, Fisher’s
exact test or a chi-square test was used. Differences between
numeric variables were tested with Student’s t-test or a
Mann-Whitney U-test, where appropriate. Correlations
were tested with Spearman’s rank-order or Pearson’s
correlation coefficient. The possible factors identified in
the univariate analyses were entered into a logistic regres-
sion analysis to determine the independent predictors of
hepatosteatosis. Hosmer-Lemeshow goodness-of-fit statis-
tics were used to assess model fit. P,0.05 was considered to
be statistically significant.
& RESULTS
A total of 211 subjects were included in the study. Of
these subjects, 57 did not have NAFLD (the control group)
and 154 had NAFLD. Within the NAFLD group, 48 patients
had grade 1, 69 patients had grade 2 and 37 patients had
grade 3 hepatosteatosis. The NAFLD and control groups did
not differ in terms of gender, age or BMI. The NAFLD
group had significantly higher fasting blood glucose (FBG)
(p= 0.005), uric acid (p= 0.001), aspartate aminotrans-
ferase (AST) (p,0.0001), alanine aminotransferase (ALT)
(p,0.0001), c-glutamyltransferase (GGT) (p,0.0001), alka-
line phosphatase (ALP) (p= 0.028), HbA1c (p,0.0001),
ferritin (p,0.0001), insulin (p= 0.016), C-peptide (p= 0.001),
HOMA-IR (p= 0.003), total cholesterol (p= 0.001), triglycer-
ide (TG) (p= 0.001) and white blood cell (WBC) (p= 0.04)
levels. In contrast, the NAFLD group had significantly
lower 25(OH)D levels (p,0.0001) compared with those of
the control group (Figure 1).
There was no significant difference in other measure-
ments between the two groups. The demographic features
and laboratory measurements of the subjects are shown in
Table 1.
There was a gradual decline in the mean 25(OH)D levels
as the grade of NAFLD increased. However, 25(OH)D levels
did not differ significantly between the 3 grades of NAFLD.
Uric acid (p,0.0001), AST (p= 0.04), ALT (p= 0.001), and
HOMA-IR (p= 0.004) levels were significantly different
between the 3 grades of NAFLD. The urinary albumin/
creatinine ratio differed significantly between the NAFLD
grades and the controls (p= 0.01). Among the 3 grades, only
patients with grade 3 NAFLD had a significantly higher
urinary albumin/creatinine ratio than did the controls
(p= 0.002).
The levels of 25(OH)D were significantly correlated with
BMI (r = -0.173, p= 0.013), HbA1c levels (r = -0.198, p= 0.004),
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the urinary albumin/creatinine ratio (r = -0.267, p= 0.001),
FBG levels (r = -0.151, p= 0.03), the erythrocyte sedimenta-
tion rate (ESR) (r = -0.321, p,0.0001), uric acid levels
(r = 0.159, p= 0.022), total cholesterol levels (r = -0.239,
p= 0.001), LDL-C levels (r = -0.199, p= 0.004) and HDL-C
levels (r = -0,193, p= 0.005). The results of the logistic
regression analysis are shown in Table 2.
& DISCUSSION
This study showed that individuals with NAFLD have
significantly lower serum 25(OH)D levels compared with
those of individuals without NAFLD. However, we failed to
demonstrate a difference in serum 25(OH)D levels between
the three grades of NAFLD.
Several studies have investigated the role of vitamin D
status in NAFLD. Jablonski et al. investigated the role of
25(OH)D in NAFLD patients in an integrated healthcare
delivery system in the U.S. These researchers matched the
NAFLD group with a presumably healthy population that
did not undergo liver US. They found a strong inverse
relationship between NAFLD and 25(OH)D levels (9). Rhee
et al. found a minor but significant difference in 25(OH)D
levels between patients with and without NAFLD (38.7¡9.0
vs. 39.7¡9.7 nmol/l)(10). In another study, plasma vitamin
D concentrations were quantified in 148 consecutive biopsy-
proven NAFLD patients and 39 controls. The researchers
found that vitamin D levels were significantly lower in
NAFLD patients compared with healthy controls. Higher
NAFLD activity scores were associated with lower plasma
concentrations of vitamin D(6). Targher et al. studied 60
consecutive patients with NAFLD and 60 clinically healthy
volunteers during the winter months (11). The researchers
performed a liver biopsy to confirm NAFLD. They found
significantly lower levels of serum 25(OH)D in NAFLD
patients than in controls. Additionally, 25(OH)D concentra-
tions were inversely related to the degrees of steatosis,
necroinflammation and fibrosis. The researchers chose lean,
healthy subjects as the control group, so the difference in
vitamin D levels may also have been influenced by obesity
per se. In our study, there was no significant difference
between the subjects with NAFLD and without NAFLD
regarding BMI. Therefore, we think that we can eliminate
the effect of obesity on the levels of 25(OH)D. In our study,
although there was a gradual decline in the mean levels of
25(OH)D as the grade of NAFLD increased, this decline did
not reach significance.
Barchetta et al. investigated vitamin D status in NAFLD
patients diagnosed by ultrasonographic evaluation (12).
Figure 1 - Comparison of 25(OH)D levels (ng/dl) between the
NAFLD and the control groups.
Table 1 - General characteristics and laboratory measurements among the groups.
Control
(n = 57)
NAFLD
(n = 154) p
Age (years) 48.9¡11.0 46.3¡10.7 NS
Sex (n, %) =:27 (47.4%), R:30 (52.6%) =:66 (42.9%), R:88 (57.1%) NS
BMI (kg/m2) 31.9¡4.3 31.7¡7.6 NS
25(OH)D (ng/dl) 20¡13.6 12.3¡8.9 ,0.0001
FBG (mg/dl) 90.7¡12.5 98.9¡20.4 0.005
BUN (mg/dl) 26.3¡7.6 25.1¡.,4 NS
Creatinine (mg/dl) 0.8¡0.15 1.02¡0.18 NS
Uric acid (mg/dl) 4.8¡1.3 5.5¡1.3 0.001
AST (IU/l) 22.5¡6.5 34.5¡18.1 ,0.0001
ALT (IU/l) 21.3¡8.2 47.3¡34.0 ,0.0001
GGT (IU/l) 24.5¡21.7 41.3¡29.9 ,0.0001
ALP (IU/l) 81.2¡49.1 92¡53 0.028
Total protein (g/dl) 7.3¡0.4 7.4¡0.4 NS
Albumin (g/dl) 4.2¡0.4 4.2¡0.3 NS
HbA1c (%) 5.6¡0.5 6.0¡0.7 ,0,0001
Ferritin (ng/ml) 39.0¡33.3 66.7¡52.3 ,0.0001
Insulin (mIU/ml) 12.6¡11.5 13.7¡9.6 0.016
C-peptide (ng/ml) 2.54¡1.70 3.10¡1.81 0.001
HOMA-IR 2.85¡2.73 3.45¡3.29 0.003
ESR (mm/hour) 15.2¡14.0 18.4¡15.3 NS
Urinary albumin/creatinine ratio (g/mg) 7.0¡10.5 13.3¡37.8 NS
Total cholesterol (mg/dl) 180.3¡29.1 199.9¡40.5 0.001
HDL-C (mg/dl) 45.0¡10.1 44.9¡12.7 NS
LDL-C (mg/dl) 115.8¡26.9 122.8¡37.7 NS
TG (mg/dl) 108.1¡57.3 152.6¡99.6 0.001
WBC (/dl) 7042.9¡1870.8 7574.7¡1907.7 0.04
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They found a significant correlation between the fatty liver
index and 25(OH)D levels. However, they did not mention
the months during which the serum samples were collected
and did not compare the 25(OH)D levels between the 3 grades
of NAFLD. Our study is in accordance with Targher’s and
Barchetta’s studies, except that 25(OH)D levels did not differ
significantly between the 3 grades of NAFLD, although
there was a gradual decline in the levels of 25(OH)D. This
discrepancy may stem from different UV light exposure in
the different seasons during which these studies were
conducted. In our country, dairy products are not enriched
with vitamin D. However, in the above-mentioned studies,
the researchers did not mention whether dairy products are
enriched with vitamin D in their countries. In the first study,
both the NAFLD and the control subjects had mean 25(OH)D
levels above normal levels. In the second study, the control
subjects had normal mean 25(OH)D levels. In our study, only
the control subjects had mean 25(OH)D levels higher than
the lower normal limit (20 ng/ml). In this study, we also
performed specific blood tests to exclude other chronic liver
diseases, such as autoimmune hepatitis, Wilson’s disease and
hemochromatosis. Previous studies did not address these
possible causes of chronic liver disease in which vitamin D
metabolism may also be altered.
In our study, vitamin D levels were negatively correlated
with total cholesterol levels. It was previously shown that
vitamin D directly regulates the metabolism of FFAs via its
action on peroxisome proliferator-activated receptor gamma
(PPAR-c)(12). There may be a link between vitamin D and
lipid metabolism in the liver; theoretically, increased FFAs
in the blood may increase fat storage in the liver, resulting
in NAFLD. Apolipoprotein E (APOE) is a plasma protein
that is involved in lipid transport and metabolism. Three
alleles, e2, e3 and e4, at the APOE locus on chromosome 19
determine three isoforms: APOE2, APOE3 and APOE4,
respectively. Sazci et al. have found that the APOE e3
allele was overrepresented in non-alcoholic steatohepatitis
(NASH) patients (e3 = 97.37% in NASH vs. 82.45% in
controls)(13). In that study, APOE polymorphism was also
significantly associated with NASH. It was previously
shown that the APOE e4 allele was associated with higher
serum vitamin D levels in mice and that APOE2 and APOE3
mice had lower 25(OH)D levels compared with those of
APOE4 mice (14). We can hypothesize that patients carrying
the APOE e3 allele might have both hepatosteatosis and
vitamin D deficiency due to a combined mechanism.
It is known that vitamin D has immunomodulatory effects.
In LPS-stimulated murine macrophages, 1.25(OH)2D3 upre-
gulates the inhibitor of NF-kB (IkB-a) by increasing mRNA
stability and decreasing IkB-a phosphorylation. This increase
in IkB-a levels leads to a reduction in the nuclear transloca-
tion of NF-kB, thereby causing a decline in activity. Given the
key role of NF-kB as a transcription factor for inflammatory
mediators, it could be suggested that 1.25(OH)2D3 has
anti-inflammatory action in macrophages (15). In the liver,
vitamin D suppresses fibroblast proliferation and collagen
production and it was recently shown that vitamin D
deficiency was associated with a low rate of sustained
virological responses in patients affected by HCV under
interferon-alpha therapy (16,17). In the present study,
inflammatory markers such as ferritin and WBC levels were
found to be significantly higher in patients with NAFLD and
vitamin D levels were negatively correlated with the ESR. It is
possible that vitamin deficiency stimulates inflammation,
together with hyperlipidemia and insulin resistance, thus
leading to NAFLD.
The main limitation of this study is the determination of
hepatosteatosis by US, without liver biopsy. We also could
not follow the patients after vitamin D replacement to
determine whether their hepatosteatosis did return to
normal.
In conclusion, in this study, we found lower serum
25(OH)D levels in NAFLD patients than in subjects without
NAFLD. However, we did not find a significant relationship
between the severity of steatosis and 25(OH)D levels. This
finding may have been related to low UV light exposure in
the winter months or to genetic differences between
different cultures. It is not known whether vitamin D
supplementation would decrease NAFLD. Interventional
experimental and prospective clinical studies are required
to establish the causality between vitamin D status and
NAFLD.
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